Overexpressed LEDGF is a novel biomarker of poor prognosis in patients with cervical cancer

Lens epithelium-derived growth factor (LEDFG) can prevent cells apoptosis by activating stress proteins and anti-apoptotic protein, which are involved in the development of a variety of malignancies as some studies have shown. However, little is known about the role of LEDGF in cervical cancer. In this study, the authors collected 95 cases of the cervical cancer tissue samples and its matching tissue adjacent to carcinoma diagnosed by the Department of Pathology. mRNA expression of LEDFG in randomly selected 20 cervical cancer tissues and 20 adjacent normal tissues was detected by quantitative real-time PCR (qRT-PCR). LEDFG protein expression in randomly selected 20 cervical cancer tissues and 20 adjacent normal tissues was detected by immunohistochemistry (IHC) and Western Blot (WB). All patients were followed up for about three years. The authors found that both mRNA and protein expression level of LEDFG was significantly higher in cancer tissues compared with normal controls (p < 0.05) and this overexpression was significantly correlated with the histologic grade, the immersion depth of interstitial, the invasion of vessel, and lymph node status of cervical cancer. Furthermore, the three-year survival rate of 34 patients with LEDGF positive expression having a survival rate of three years was 57.6%. The survival rate of three years with negative expression was 91.7%. The survival rate of patients with LEDGF positive expression was significantly lower than those of the negative expression (p < 0.01). In conclusion, the present results suggest that LEDFG expression is an independent prognostic biomarker for cervical cancer.

Cervical cancer; LEDGF; Immunohistochemistry; Western Blot; RT-PCT.

[1] Torre L.A., Freddie B., Siegel R.L., Jacques, F., Joannie L.T., Ahmedin J.: “Global cancer statistics, 2012”. CA Cancer J. Clin., 2015, 65, 87.

[2] Catherine D.M., Jacques F., Silvia F., JérMe V., Freddie, B., David, F., et al.: “Global burden of cancers attributable to infections in 2008: a review and synthetic analysis”. Lancet Oncol., 2012, 13, 607.

[3] Rebecca, S., Deepa, N., Ahmedin, J.: “Cancer statistics, 2013”. CA Cancer J. Clin., 2013, 63, 11.

[4] Zur Hausen H.: “The search for infectious causes of human cancers: where and why”. Virology, 2009, 392, 1.

[5] Ljubojevic S., Skerlev M.: “HPV-associated diseases”. Clin. Dermatol., 2014, 32, 227.

[6] Yu-Xuan X.U., Cui Y.S., Geng J.X.: “Gene analysis of HPV E6/E7 mRNA in cervical cells of 968 cases”. Maternal & Child Health Care of China, 2015, 30, 617.

[7] White E.A., Johanna W., Hassan J., Howley P.M.: “Genus beta human papillomavirus e6 proteins vary in their effects on the transactivation of p53 target genes”. J. Virol., 2014, 88, 8201.

[8] Clelia M., Giulia G., Carlo F., Giuseppe M., Giuseppe S., Antonio M.: “Role of inflammation and oxidative stress in post
menopausal oestrogen
dependent breast cancer”. J Cell Mol Med., 2014, 18, 2519.

[9] Pani G., Galeotti T., & Chiarugi P.: “Metastasis: cancer cell's escape from oxidative stress”. Cancer Metastasis Rev., 2010, 29, 351.

[10] Mena S., Ortega A., Estrela J.M.: “Oxidative stress in environmental- induced carcinogenesis”. Mutat. Res., 2008, 674, 36.

[11] Basu A., Rojas H., Banerjee H., Cabrera I.B., Perez K.Y., De L.M., et al.: “Expression of the stress response oncoprotein ledgf/p75 in human cancer: a study of 21 tumor types”. Plos One, 2012, 7, 277.

[12] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: “Global cancer statistics”. CA Cancer J. Clin., 2011, 61, 69.

[13] Leoh L.S., Van H.B., De R.J., Filippova M., Rios-Colon L., Basu A., et al.: “The stress oncoprotein ledgf/p75 interacts with the methyl cpg binding protein mecp2 and influences its transcriptional activity”. Mol. Cancer Res., 2012, 10, 378.

[14] Stav S., Batya C., Yael T., Gila M., Shifra B.D., Alon H., et al.: “Gonadotropin- regulated lymphangiogenesis in ovarian cancer is mediated by ledgf-induced expression of vegf-c”. Cancer Res., 2009, 69, 9306.

[15] Basu A., Awa Drame., Muñoz R., Gijsbers R., Debyser Z., Leon M.D., et al.: “Pathway specific gene expression profiling reveals oxidative stress genes potentially regulated by transcription co-activator ledgf/p75 in pca cells”. Prostate, 2009, 72, 597.

[16] Singh D., Fatma N., Kimura A., Chylack L.J., Shinohara, T.: “Ledgf binds to heat shock and stress-related element to activate the expression of stress-related genes”. Biochem. Biophys. Res. Commun., 2001, 283, 943.

[17] KateIna C., Petr T., Jonas D., Sara E.A., Hélène, M., Juerg, S., et al.: “Validation and structural characterization of the ledgf/p75-mll interface as a new target for the treatment of mll-dependent leukemia”. Cancer Res., 2014, 74, 5139-5151.

[18] Singh D.P., Ohguro N., Kikuchi T., Sueno T., Reddy V.N., Yuge K., et al.: “Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts”. Biochem. Biophys. Res. Commun., 2002, 267, 373.

[19] Singh D., Kubo E., Takamura Y., Shinohara T., Kumar A., Chylack L., et al.: “Dna binding domains and nuclear localization signal of ledgf: contribution of two helix-turn-helix (hth)-like domains and a stretch of 58 amino acids of the n-terminal to the trans-activation potential of ledgf”. J. Mol. Biol., 2006, 355, 379.

[20] Daugaard M., Kirkegaard-Sorensen T.M., Aaboe M., Hoyer-Hansen M., Orntoft T., Rohde M., et al.: “Lens epithelium-derived growth factor is an hsp70-2 regulated guardian of lysosomal stability in human cancer”. Cancer Res., 2007, 67, 2559.

[21] Nishizawa Y., Usukura J., Singh D.P., Chylack L.T., Shinohara T.: “Spatial and temporal dynamics of two alternatively spliced regulatory factors, lens epithelium-derived growth factor (ledgf/p75) and p52, in the nucleus”. Cell Tissue Res., 2001, 305, 107.

[22] Singh D.P., Ohguro N., Chylack L. T., Shinohara T.: “Lens epithelium- derived growth factor: increased resistance to thermal and oxidative stresses”. Invest. Ophthalmol. Vis. Sci., 199, 40, 1444.

[23] Kuner R., Vogt M., Sultmann H., Buness A., Dymalla S., Bulkescher J., et al.: “Identification of cellular targets for the human papillomavirus e6 and e7 oncogenes by rna interference and transcriptome analyses”. J. Mol. Med., 2007, 85, 1253.

[24] Jenny L., Miriam R., Claudia L., Anja H., Rosita A., Massimo T., et al.: “Oncogenic human papillomaviruses activate the tumor-associated lens epithelial-derived growth factor (ledgf) gene”. PLoS Pathog., 2014, 10, e1003957.

[25] Desfarges S., Abderrahmani A., Hernàndez-Novoa B., Munoz M., Ciuffi A.: “Ledgf/p75 tata-less promoter is driven by the transcription factor sp1”. J Mol Biol., 2011, 414, 177.

[26] Basu A., Awa Drame, Muñoz R., Gijsbers R., Debyser Z., Leon M.D., et al.: “Pathway specific gene expression profiling reveals oxidative stress genes potentially regulated by transcription co-activator ledgf/p75 in pca cells”. Prostate, 2012, 72, 597.

[27] Stav S., Batya C., Yael T., Gila M., Shifra B.D., Alon H., et al.: “Gonadotropin- regulated lymphangiogenesis in ovarian cancer is mediated by ledgf-induced expression of vegf-c”. Cancer Res., 2009, 69, 9306.